Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS

v3.8.0.1
SUBSEQUENT EVENTS
6 Months Ended
Mar. 31, 2018
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 9 – SUBSEQUENT EVENTS 

 

In April and May 2018, the Company sold or licensed certain assets related to the squalamine program. We received upfront payments and are eligible for additional payments upon the exercise of an option to purchase additional assets, and the achievement of development and regulatory milestones, and future sales.